{"id":"NCT01280721","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]","officialTitle":"A Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11","primaryCompletion":"2014-08","completion":"2014-08","firstPosted":"2011-01-21","resultsPosted":"2019-01-17","lastUpdate":"2019-01-17"},"enrollment":135,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Autosomal Dominant Polycystic Kidney Disease ï¼ˆADPKD)"],"interventions":[{"type":"DRUG","name":"tolvaptan","otherNames":[]}],"arms":[{"label":"tolvaptan","type":"EXPERIMENTAL"}],"summary":"ADPKD patients who enrolled in Trial 156-04-251 will receive repeated oral administration of tolvaptan twice daily (morning and evening: 45mg/15mg, 60mg/30mg, or 90mg/30mg).","primaryOutcome":{"measure":"Total Kidney Volume","timeFrame":"Baseline, Month12, Month24, and Month36","effectByArm":[{"arm":"Baseline","deltaMin":1812.38,"sd":859.21},{"arm":"Month 12","deltaMin":1878.82,"sd":950.6},{"arm":"Month 24","deltaMin":1934.14,"sd":926.79},{"arm":"Month 36","deltaMin":2214.28,"sd":842.87}],"pValues":[]},"eligibility":{"minAge":"23 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":7,"countries":["Japan"]},"refs":{"pmids":["29123425"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":135},"commonTop":["Thirst","Nasopharyngitis","Pollakiuria","Polyuria","Back pain"]}}